Skip to main content
Premium Trial:

Request an Annual Quote

Louis Drapeau, Philip Padou, Richard Begley, Per Petersen, Ismail Kola, Steven Kriegsman, Mark Ahn, Stephen Galliker, Sanford Hillsberg

Bio-Rad last week appointed Louis Drapeau to its audit committee. He will stand for election at a board meeting in April. Drapeau fills the space left open by the death late last year of Philip Padou.
Drapeau is currently CFO and senior vice president of finance at Nextar Therapeutics. He also served as CEO, CFO, and senior vice president at BioMarin Pharmaceutical, and was an executive in accounting and he serves on the board of directors at Inflazyme Pharmaceuticals.

PerkinElmer last week appointed Richard Begley vice president and general manager of its Analytical Sciences business.
In this position, Begley will “develop and lead the growth strategy” globally for the firm’s entire portfolio of analytical instrumentation, which includes chromatography, atomic and molecular spectroscopy, thermal analysis, and laboratory information management systems.
Begley joins PerkinElmer from Ensemble Discovery, where he was president and CEO. Before this he was CEO and president of 454 Life Sciences.

Per Petersen has been appointed to Invitrogen’s board of directors after retiring from his post at the chairman of R&D at Johnson & Johnson, the company said this week.
At J&J, Peterson was responsible for the Office of Science and Technology, the R&D Council, and the cell therapy research and activities. Prior to that, Peterson was chairman of the Department of Immunology at the Scripps Research Institute.

Ismail Kola has been named CSO and senior vice president of discovery research at the Schering-Plough Research Institute, the company said this week. Kola replaces Catherine Strader, who now is senior vice president of science and technology.
Kola will now be responsible for a 1,000-person team of researchers in the US and in Italy, and will be a member of the company’s operations management team.
Strader will be involved in external science and technology enterprises such as business development and licensing.

RXi Pharmaceuticals, a pure-play RNAi technology company and subsidiary of CytRx, has formed a five-member board of directors.
The board includes: Todd Woolf, president and CEO of RXi; Steven Kriegsman, who was president and CEO of CytRx; Mark Ahn, president and CEO of biopharmaceutical company Hana Biosciences; Stephen Galliker, executive vice president of finance and administration and CFO of Dyax; and Sanford Hillsberg, managing partner at the law firm Troy & Gould Professional.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.